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A B S T R A C T
Nanoparticle engineering is a well-deﬁned technique employed as a novel and eﬀective method in drug design
and delivery. It is widely used to control particle size, as well as the morphological and physicochemical
properties of active pharmaceutical ingredients. Furthermore, it serves as a method of pre-dispersion preparation
for various dosage form developments. Nanotechnology produces nanomaterials with enhanced properties in
terms of solubility, dissolution and permeability. In this work, ultrasonic-assisted precipitation was employed to
produce nanosuspensions of poorly water-soluble loratadine, using diﬀerent stabilizers. The objective of our
study was attempting to prepare solid nanoparticles of loratadine to be used as a possible intermediate for
designing various dosage forms. The eﬀects of the type(s) and concentration(s) of stabilizer(s) on mean particle
size were assessed. Optimal process parameters required to produce homogeneous nanoparticles with particle
size below 500 nm and polydispersity less than 0.3 were determined both for precipitation and ultrasonication.
Pre-dispersions were evaluated for their particle size, polydispersity index and zeta potential. Freeze-drying was
employed to produce dry nanoparticles. Particle size, particle size distribution and zeta potential of the dried
nanoparticles were measured after reconstitution in water. Besides thermal analysis using DSC and structural
analyses (XRPD and FT-IR), the morphological characteristics and dissolution behaviors were also investigated.
The selected freeze-dried nanoparticles had a mean particle size range of 353–441 nm, a polydispersity index
ranging between 0.167 and 0.229 and a zeta potential between−25.7 and−20.7mV. These results suggest that
material and process parameters were successfully optimized. DSC and XRPD spectra conﬁrmed interactions
between the formulation's components during freeze-drying. The solid nanoparticles showed 30–42% of cu-
mulative release after 10min compared to less than 1% of dissolution characterizing loratadine without pre-
processing. This study demonstrates that preparing dried loratadine nanoparticles suitable for designing eﬀec-
tive drug preparations is a feasible approach.
1. Introduction
Nanotechnology is one of the most widely used approaches to
overcome the inconveniences of solubility and poor bioavailability, as
well as a method utilized to produce intermediate compounds for dif-
ferent dosage forms. Nanosuspensions have numerous outstanding ad-
vantages, including enhanced solubility and dissolution rate of other-
wise poorly water-soluble drug compounds, high adhesiveness to
biological surfaces, as well as easy formulation and scale up. Also, they
allow reaching high drug concentrations and applicability in any types
of drug formulations, such as preparations for oral, parenteral, dermal,
pulmonary, ocular and nasal delivery (Bartos et al., 2015a; Chen et al.,
2015; Merisko-Liversidge and Liversidge, 2008; Patravale et al., 2004;
Pawar et al., 2014).
Nanosuspensions are colloidal dispersions of drug particles in the
submicron size (mean particle size less than 1 μm) and need to be sta-
bilized by a minimum amount of suitable ionic or/and steric stabilizer.
The drug compounds (active pharmaceutical ingredients, APIs) in-
cluded in nanosuspensions can exist in crystalline or amorphous forms.
The produced liquid pre-dispersion can be converted into intermediate
solid products, such as powder, by means of drying or into a semi-solid
formulation, such as gel (Bartos et al., 2016; Hao et al., 2015; Lindfors
et al., 2007; Rabinow, 2004).
Top-down and bottom-up procedures are generally applied for the
preparation of nanosuspensions. The top-down approach includes
comminution of large particles into nanoparticles, while the bottom-up
approach employs the precipitation of nanoparticles from dissolved
drug molecules. Although the top-down method is preferred in the
pharmaceutical industry, the bottom-up method has the potential for
producing homogenous nanoparticles with lower energy input
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(Agrawal and Patel, 2011; Du et al., 2015; Iurian et al., 2017;
Möschwitzer, 2010; Müller et al., 2011; Rahim et al., 2017).
Antisolvent precipitation is the most common and eﬀective bottom-
up technique currently applied in nanosuspension preparation. Its ad-
vantages include simplicity and cost-eﬀectiveness. The method of an-
tisolvent precipitation is based on the principle that a compound's so-
lubility in a water-miscible organic solvent can be modiﬁed by adding
an antisolvent which promotes precipitation. During precipitation,
stabilizers dissolved in the antisolvent get absorbed on the crystal
surfaces to inhibit further crystal growth (Ambrus et al., 2009;
Matteucci et al., 2006).
Ultrasonication has been introduced as an eﬀective method to be
combined with precipitation to achieve an enhanced particle size re-
duction and to control the processes of nucleation and crystallization.
When applied on liquid, ultrasound waves are characterized by a cyclic
succession of expansion and compression phases, with compression
cycles exerting a positive pressure and pushing the liquid molecules
together, while expansion cycles exert a negative pressure and pull the
molecules apart. Besides, ultrasound waves intensify mass transfer by
initiating cavitation. Cavitational bubbles are formed during the ne-
gative-pressure phase. The phenomena of the formation, growth and
subsequent collapse of microbubbles release a large magnitude of en-
ergy. When a bubble collapses, a conﬁned hot spot with high tem-
perature and pressure is formed, releasing powerful shock waves. Thus,
mixing of the solvent and the antisolvent is enhanced, leading super-
saturation of the mixture. Furthermore, the implosion of vacuum bub-
bles breaks down particles. The ﬁnal results of this process are depen-
dent on sonication duration and intensity, on the sonotrode's length and
depth of immersion, as well as on temperature (Anil et al., 2016; Bartos
et al., 2015b; Dhumal et al., 2008; Jiang et al., 2012; Liu et al., 2012;
Mishra et al., 2015; Wu et al., 2013; Xia et al., 2010; Zhang et al.,
2006).
In terms of stability, liquid nanosuspensions are characterized by
physical and chemical instability attributed to aggregation, agglom-
eration, Ostwald ripening and changes of the crystalline state (Lindfors
et al., 2007). Thus, an immediate transformation of nanosuspensions
into solid nanoparticles facilitates stability and allows processing to
produce various dosage forms. Freeze-drying is one of the most widely
used methods for drying nanosuspensions. However, even the freeze-
drying process may induce stress, which in turn inﬂuences the physical
stability of nanosuspensions. The stress evoked during the freezing and
drying phases can destabilize the colloidal system. During freezing, a
phase separation is experienced, yielding ice and a cryo-concentrated
solution phase. This highly concentrated system may promote ag-
gregation of the particles. Moreover, the crystallization of ice may
produce a mechanical stress on the nanosized particles, also leading to
their destabilization. On the other hand, the dehydration phase involves
the removal of ice and unfrozen water which remained dissolved or
adsorbed on the solid phase (Abdelwahed et al., 2006a, 2006b;
Beirowski et al., 2011; Quintanar-Guerrero et al., 1998; Van
Eerdenbrugh et al., 2008; Wu et al., 2011).
Consequently, numerous parameters play a signiﬁcant role in the
particle size and properties of nanosuspension-based freeze-dried na-
noparticles, including drug concentration, type(s) and concentration(s)
of stabilizer(s), solvent type and solvent to antisolvent ratio, as well as
sonication and drying conditions and additives. Thus, nanosuspension
preparation with ultrasonic-assisted precipitation and freeze-drying of
these nanosuspensions are complex asks that require a careful selection
of both process and material parameters.
Loratadine (LOR), a second-generation histamine H1 receptor an-
tagonist, is the most frequently prescribed antihistamine drug for the
treatment of allergic conditions, such as rhinitis, urticaria and atopic
dermatitis. Recent studies have also reported LOR as a safe and eﬀective
emergency therapy for the management of bone pain induced by
granulocyte-colony stimulating factors (G-CSFs). It is reported that10
mg of LOR is eﬀective against NSAID-resistant severe G-CSF-induced
bone pain (Moore and Haroz, 2016; Romeo et al., 2015). The com-
pound's properties classify LOR as a class II agent according to the
biopharmaceutical classiﬁcation system, characterized by poor water
solubility (3.03 μg/ml) and high permeability (logP=5). It is a weak
base with a reported pKa value of 5.25 at 25 °C, responsible for its pH-
dependent solubility, and consequent variability in bioavailability
(Dagenais et al., 2009; Han et al., 2004; Popović et al., 2009). Various
techniques have been applied to enhance the solubility and dissolution
properties of LOR, including solid dispersion, inclusion with ß-cyclo-
dextrin derivatives, micellar solubilization and self-microemulsifying
systems. Other studies have also reported the preparation of a LOR in
situ gel as niosomes, as well as a nanoparticle loaded thermosensitive in
situ gel for nasal delivery(Frizon et al., 2013; Hin Teng et al., 2015; Li
et al., 2015; Nacsa et al., 2008, 2009; Popović et al., 2009; Vyshnavi
et al., 2015).
The present research is known to be the ﬁrst work to utilize the
ultrasonic-assisted antisolvent precipitation approach to prepare LOR
nanosuspensions (LNs), using cellulose derivatives (i.e. hydro-
xylpropylmethylcellulose, HPMC), polyvinylpyrrolidone (PVP-K25),
Poloxamer 188 (Pluronic F 68), polysorbate (Tween 80) and sodium
lauryl sulfate (SLS) either as a single stabilizer or in combination. The
eﬀects of the type(s) and concentration(s) of the stabilizer(s) on mean
particle size were investigated. The novelty of our research includes the
preparation of a nanoscale LOR powder that can be used as an inter-
mediate for designing diﬀerent dosage forms.
2. Materials and methods
2.1. Materials
LOR was purchased from Teva Ltd. (Budapest, Hungary).
Hydrophilic polymers; Polyvinylpyrrolidone K-25 (PVP-K25) was sup-
plied by ISP Customer Service GmBH (Cologne, Germany) and hydro-
xypropylmethylcellulose E50LV (HPMC) was supplied by Colorcon
(Budapest, Hungary). Pluronic F68, a synthetic tri-block copolymer,
was purchased from BASF (Ludwigshafen, Germany). The non-ionic
surfactant Tween 80 was supplied by Fluka Chemika (Buchs,
Switzerland), the anionic surfactant sodium lauryl sulfate (SLS) was
supplied by Molar Chemicals Ltd. (Budapest, Hungary), methanol was
purchased from FreeHand Ltd. (Pecs, Hungary), ethanol was supplied
by Spectrum-3D (Debrecen, Hungary), and D-(+)-trehalose (TRE) was
supplied by Sigma-Aldrich (New York, USA). Water was puriﬁed by
double distillation.
2.2. Methods
2.2.1. Preliminary studies with LOR: solubility tests
Excess drug amount was added into 5ml of distilled water or
phosphate buﬀer solution (PBS; pH 7.4), followed by shaking at 25 °C
for 24 h. A sample was taken, ﬁltered and the amount of dissolved LOR
was measured spectrophotometrically (Unicam UV/VIS
Spectrophotometer, Cambridge, UK). Solubility in other solvents was
determined gravimetrically by adding an excess amount of LOR into
5ml of diﬀerent water-miscible solvents, such as ethanol, acetone and
methanol. The drug-containing solution was stirred at 4000 rpm for 1 h
at room temperature (25 °C), and then 1ml of each solution was ﬁltered
into a drying dish. The ﬁltrate was allowed to stand for solvent eva-
poration, and the residual mass was weighed on a daily basis, using an
analytical balance (Mettler Toledo Ax 205, d=0.01mg) to make sure
of the total removal of the solvent. Constant mass indicates the solu-
bility in 1ml of the solvent used.
2.2.2. Preparation of loratadine nanosuspension (LN)
After the preliminary studies, LNs were prepared using the pre-
cipitation-ultrasonication method. LOR was dissolved in ethanol ac-
cording to its solubility, while the stabilizer(s) was (were) dissolved in
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water. For stabilizer mixtures of Tween 80 or F68 plusPVP-K25, one of
the stabilizers (F68, Tween 80) was added to the solvent phase, while
the other one (PVP-K25) was added to the antisolvent phase. Both so-
lutions were ﬁltered through a 0.45 μm ﬁlter (FilterBio PES Syringe
Filter, Labex Ltd., Budapest, Hungary). The fresh-made LOR solution
was rapidly introduced into the cool antisolvent under sonication using
a UP 200 s Ultrasonic processor (HielscheruUltrasonics GmbH,
Germany) and diﬀerent conditions in terms of energy power, sonication
time and sonication temperature. The temperature of sonication was
controlled (Julabo F32, JULABO GmbH, Germany). LNs were stirred at
room temperature for 24 h to remove the organic solvent.
2.2.3. Preparation of dried loratadine nanoparticles (DLN)
As detailed before, dried nanoparticles are more preferable for their
chemical and physical stability. Freeze-drying was performed in a
Scanvac, CoolSafe 100-9 Pro type apparatus (LaboGeneApS, Lynge,
Denmark) equipped with a 3-shelf sample holder unit, recessed into the
drying chamber. Nanosuspensions were lyophilized with 5% w/v TRE.
The process was controlled by a computer program (Scanlaf
CTS16a02), temperature and pressure were recorded continuously. The
drying chamber where the samples were frozen had a temperature
range between −97 °C and −88 °C. The process parameters are shown
in Table 1.
2.2.4. Preparation of physical mixtures
Physical mixtures (PMs) corresponding to the composition of the
nanosuspensions were prepared as reference samples by blending LOR
and F68 in 1.25:1 weight ratio for PM1 or LOR, F68 and PVP-K25in
1.25:1:1 weight ratio for PM2, in a Turbula mixer (Turbula System
Schatz; Willy A. Bachofen AG Maschinenfabrik, Basel, Switzerland)
using 60 rpm for 10min.
2.2.5. Particle size and zeta potential characterization for LNs
The mean particle size (MPS), zeta potential (ZP) and polydispersity
index (PDI) of LNs were measured by laser diﬀraction using a Malvern
Nano ZS zetasizer (Malvern Instrument, UK), using water as the dis-
persant and setting there fractive index to 1.62.
2.2.6. Characterization of dried nanoparticles (DLN)
2.2.6.1. Scanning electron microscopy (SEM). Morphology of the LOR,
PMs and DLNs particles were characterized by scanning electron
microscopy (SEM) (Hitachi S4700, Hitachi Scientiﬁc Ltd., Tokyo,
Japan) at 10 kV. The samples were coated with gold-palladium (90 s)
using a sputter coater (Bio-Rad SC 502, VG Microtech, Uckﬁeld, UK)
and an electric potential of 2.0 kV at 10mA for 10min. Air pressure was
set to 1.3–13.0 mPa.
2.2.6.2. X-ray powder diﬀraction (XRPD). The structures of lyophilized
nanoparticles and raw materials were characterized using a BRUKER
D8 Advance X-ray powder diﬀractometer (Bruker AXS GmbH,
Karlsruhe, Germany) with Cu K λI radiation (λ=1.5406 Å) and a
VÅNTEC-1 detector. Powder samples were scanned at 40 kV and 40mA,
with an angular range of 3° to 40° 2θ, at a step time of 0.1 s and a step
size of 0.01°.The degree of crystallinity (crystallinity index, %Xc) was
calculated based on the following formula, where A is the area under
the whole curve and pure LOR was considered as 100% crystalline.
=
+
∗
A
A A
Xc 100crystalline
crystalline amorphous (1)
2.2.6.3. Diﬀerential scanning calorimetry (DSC). Thermal analysis was
carried out using a diﬀerential scanning calorimeter (Mettler Toledo
DSC 821e, Mettler Inc., Schwerzenbach, Switzerland). About 3–5mg of
powder was accurately weighed into DSC sample pans, which were
hermetically sealed and lid pierced. An empty pan was used as a
reference in an inert atmosphere under constant argon purge. The
samples were analysed in the temperature range of 25–300 °C at a
heating rate of 5 °Cmin−1.
2.2.6.4. Fourier-transform infrared spectroscopy (FTIR). FT-IR spectra of
raw materials and DLNs were obtained by a Fourier-transform infrared
spectroscope (Thermo Nicolet AVATAR 330, USA) equipped with the
GRAMS/AI ver. 7program. Samples were grounded and compressed
into pastilles with 150mg dry KBr. The pastilles were scanned 128
times at a resolution of 4 cm−1in the wave number region
4000–400 cm−1.
2.2.6.5. Saturation solubility. Saturation solubility of PMs and selected
DLNs was investigated by adding excess amounts of the sample into
5ml of water or PBS, pH 7.4 at 25 °C. Next the samples were ﬁltered,
and the drug concentrations in the ﬁltrate were measured by UV
spectroscopy at ƛmax 248 nm.
2.2.6.6. Drug content and dissolution studies. LOR contents of the
selected DLNs were determined by dissolving 10mg of the sample in
50ml of 0.1 N HCl. After stirring the solution with a magnetic stirrer
(400 rpm) at room temperature for 24 h, it was ﬁltered and analysed.
The concentration was measured spectrophotometrically at 248 nm.
The quantities of the samples were chosen after drug content
determination, where the measured drug content was between 79 and
93% compared to the theoretical drug content. The modiﬁed paddle
method (USP dissolution apparatus, type II Pharma Test, Hainburg,
Germany) was used to characterize the dissolution rates of LOR, PMs
and DLNs. 1.11mg of pure LOR or DLN equivalent to 1.11mg of LOR in
100ml PBS, pH 7.4 was used. The paddles were rotated at 100 rpm at
37 °C. 5ml aliquots were taken at 5, 10, 15, 30, 60, 90 and 120min and
were ﬁltered. Concentrations of LOR were measured
spectrophotometrically (Unicam UV/VIS Spectrophotometer,
Cambridge, UK) at ƛmax 248 nm. The calibration curve was taken in
the concentration range of 2–20 μg/ml. The calibration curve was linear
throughout the whole range tested, and was described by the equation
A=0.0388 conc (R2= 0.9997). The slope was 0.039. At the maximum
absorption of LOR, no absorption was detected for the excipients we
used. The limit of detection and the limit of quantiﬁcation for LOR were
0.401 and 1.216 μg/ml, respectively. The aliquots taken were replaced.
However, sink conditions were not maintained during the dissolution
process due to the poor solubility of LOR.
2.2.7. Model-independent kinetics of dissolution proﬁles
Dissolution eﬃciency (DE) of the samples was determined by cal-
culating the percentage of the ratio of the area up to time t divided by
the area that described 100% dissolution at the same time (Khan,
1975).
∫
= ×DE
y X dt
y X t
% 100%
t
0
100 (2)
Table 1
Freeze-drying parameters used for LNs.
Process Time
(h:min)
Chamber
pressure
(mbar)
Product
temperature (°C)
Shelf
temperature (°C)
Freezing 01:00 – −39 −40
Primary
drying
02:00 −40 to −39 −40
05:20 0.01 −38to −33 −20
06:45 −32 to −27 0
Secondary
drying
18:00 −26 to −25 +10
18:40 0.01 −25 to −24 +20
27:30 −23 to −5 +30
36:10 −4 to +4 +30
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Relative dissolution (RD) with respect to the raw LOR at 60min was
calculated using the following formula:
=RD min DE min
DE LOR
60 % 60
% 60min (3)
The trapezoidal method was used to calculate the area under the
curve (AUC). AUC is the sum of all trapezia:
∑=
− +
=
=
− −AUC
t t y y( )( )
2i
i n
i i i
1
1 1 1
(4)
where ti represents the time point and yi is the percentage of sample
dissolved at time ti. Mean dissolution time (MDT) was calculated as
follows (Costa and Lobo, 2001):
=
∑ ∆
∑ ∆
−
−
MDT
t M
M
i
n
mid
i
n
1
1 (5)
where i is the dissolution sample number, n is the number of dissolution
times, tmid is the time at the midpoint between times ti and ti−1 and ΔM
is the amount of LOR dissolved (mg) between times ti and ti−1.
3. Results and discussion
3.1. Preliminary studies
3.1.1. Solubility of LOR in diﬀerent solvents and selection of the optimal
organic solvent
LOR showed poor solubility in water and PBS (2.21×10−3 and
4.88×10−4 mg/ml, respectively) On the contrary, it is freely soluble
in organic solvents such as ethanol, methanol and acetone (662.8,
563.1 and 445.1mg/ml, respectively). Based on our preliminary tests,
ethanol was used as an organic solvent with high LOR solubility. It is
water miscible with low viscosity which guarantees a higher diﬀusion
rate and the formation of many nuclei, and thus a smaller particle size.
Moreover, the higher solubility of the drug in the organic solvent is
preferable for a higher drug concentration which supports super-
saturation.
3.2. Selection of process parameters
To prepare nanoparticles, the proper design of the experiment is
inevitable, so process parameters should be cautiously adjusted to
support nanoscale production. In case of ultrasonic-assisted precipita-
tion, both precipitation and sonication parameters need to be deﬁned
and selected in the light of the particle size. To optimize this process,
the drug amount and the stabilizer's type and concentration were ﬁxed
at 100mg and 0.2% w/v of F68, respectively, and diﬀerent solvent:
antisolvent ratios, sonication temperatures, sonication times and soni-
cation powers were applied at ﬁxed freeze-drying conditions (Fig. 1).
Using a solvent: antisolvent ratio of1:20 at ﬁxed 50%, 4 °C, 30min
sonication amplitude, temperature and process length, respectively, we
were unable to produce nanoparticles, because the stabilizer's con-
centration was too low to cover the newly formed surfaces, leading to
crystal growth with an average particle size of 2.82 μm. On the other
hand, solvent: antisolvent ratios of 1:40 and 1:60 under the same so-
nication conditions yielded nanoscale particles with approximately
246.5 ± 1.83and 238.6 ± 2.31 nm MPS, respectively.
Ultrasonic amplitudes of 50, 70, and 100% were applied at the 1:40
solvent/antisolvent ratio for 30min and 4 °C. Particles size eﬃciently
decreased to approximately 246 nm at 50% amplitude. However, no
signiﬁcant reduction was achieved with further increment, when MPS
was at the order of 235 nm ± 4.45. On the other hand, the length of
sonication had a crucial eﬀect on particle size when the power and
temperature of sonication were ﬁxed at 50% and 4 °C, respectively.
10min were too short to produce nanoparticles (MPS 1.103 μm), and
20min produced unstable LNs with crystals precipitating immediately.
A sonication time of 30min was an appropriate sonication length to
produce LNs. Sonication temperature aﬀects particle size in a well-
known manner: generally, the lower the temperature is, the smaller the
crystals are. Reasonably, high temperature increases the drug's solubi-
lity with a consequent decrease of supersaturation and nuclei numbers.
The other explanation for the temperature eﬀect is related to a higher
rate of diﬀusion and to the kinetic reaction at the crystal surface, re-
sulting in increased crystal growth (Matteucci et al., 2006). For ex-
ample, for nitrendipine, particle size was reduced from 4.43 μm to
211 nm when precipitation temperature was changed from 35 to 3 °C,
and for carvedilol 221 nm MPS was yielded when sonication tempera-
ture was controlled at 4–8 °C (Liu et al., 2012). In our study, reducing
temperature from 25 to 4 °C reduced particle size from 3.21 μm to the
nanoscale when all other parameters were ﬁxed.
The process parameters selected for F68 were used for the other
stabilizers tested to evaluate the eﬀect of stabilizer type on particle size
of LNs. The requirements for producing nanoparticles with the lowest
particle size and a PDI less than 0.3 were previously determined to
ensure a homogenous particle size distribution.
3.3. Eﬀects of material parameters on particle size and stability of LNs
To produce a stable nanosuspension, steric and/or electrostatic
barriers must provide adequate wetting and eﬀectively prevent the
aggregation of particles. Furthermore, it is important to keep a uniform
particle size to prevent Ostwald ripening (Rabinow, 2004). Table 2
shows MPS, PDI and ZP for pure LOR and for the prepared LNs. Mean
particle size for unprocessed LOR was approximately 4.6 μm. Using
PROCESS PARAMETERS
Precipitation Sonication 
Solvent: antisolvent 
1:20 1:40 1:60
Freeze-drying
Temp (°C)  Amplitude (%)Time (min)
25
Temp (°C)  Time (h) P (mbar)
-40 36 0.014 3010 20 50 70 100
Fig. 1. Schematic diagram for the selection of process parameters.
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HPMC or PVP-K25 alone as a single stabilizer was insuﬃcient to sta-
bilize LOR nanoparticles. Adding either of these hydrophilic polymers
alone yielded high MPS (4900 ± 71.98 and 4212 ± 14.14 nm, re-
spectively) with a large particle size distribution as reﬂected by the PDI
values (0.98 ± 0.028 and 0.767 ± 0.182, respectively). This failure to
produce stable nanoparticles can be attributed to the weak adsorption
of these polymers onto LOR's surface, as well as to the poor dipole-
dipole interaction between LOR and the polymers because of a low
polar surface area of LOR (Bartzatt, 2017). SLS alone was also found to
be unsuitable to stabilize LNs. SLS-containing LNs were characterized
by an MPS of 1496.3 ± 174.57 nm and a PDI of 0.414 ± 0.109, which
can be related to the high solubility and insuﬃcient hydrophobicity of
SLS, leading to insuﬃcient and incomplete adsorption on LOR's surface
(Obeidat and Sallam, 2014). In contrast, Tween 80 and F68 were sui-
table to produce LNs when they were used on their own. Using Tween
80 and F68 yielded LNs with an MPS of 414.9 ± 9.02 and
246.5 ± 1.38 nm, respectively, with a narrow particle size distribution
(PDI was 0.217 ± 0.034 for LNs containing Tween 80 and
0.133 ± 0.03 for those containing F68). Combining SLS with F68
orPVP-K25 augmented the latter one's favourable eﬀects on nanosus-
pension stabilization, yielding an MPS less than 600 nm, while the
combination of Tween 80 or F68 with PVP-K25 did not induce any
signiﬁcant changes compared to Tween 80 or F68 alone. Diﬀerent
concentrations of F68 as single stabilizer yielded diﬀerent MPSs with
increasing diameter as concentration increased, due to a higher visc-
osity of the solutions, which hinders solvent diﬀusion and aﬀects the
transmission of ultrasonic waves.
Drug concentration had a signiﬁcant eﬀect on particle size reduc-
tion. Using a ﬁxed 1:1 ratio of 0.2% w/v of F68 and PVP-K25 as sta-
bilizers, the smallest MPS was obtained with 100mg of LOR. This can
be explained by supersaturation, which determines the nucleation
process. A higher drug concentration led to a higher rate of nucleation,
resulting in a large number of nuclei and thus a smaller particle size
(Lonare and Patel, 2013).
For stable nanosuspensions, zeta potential has to exceed±20mV
and±30mV for sterically and electrically stabilized NSs, respectively
(Agrawal and Patel, 2011). The highest zeta potentials were detected
for SLS-containing LNs due to the negative charge of this stabilizer
compound. However, their MPS and PDI values were unfavourable.
Selecting LNs for further analysis was basically established on their
MPS and PDI values as evaluation indices. ZP was not involved, as the
subsequent drying procedure could inﬂuence of the electro kinetic
potential present in nanosuspensions. Thus, although LNs containing
F68 or PVP-K25 were characterized by negative zeta potentials between
−27.8 ± 5.08 and −4.81 ± 4.11mV, LNs containing these two sta-
bilizers were selected for further analysis. While Tween 80 also proved
to be an eﬃcient stabilizer producing LNs with an acceptable ZP of
approximately −23mV, in this case particle size was higher than that
for LNs containing F68 because of a higher solubility of LOR in Tween
80 (2.25 μg/ml and 97.674 μg/ml in 0.2% w/v F68 and Tween 80, re-
spectively).
In summary, LNs suitable for further processing were prepared
using the following process parameters: 30min sonication time, 50%
amplitude of sonication power, 4 °C sonication temperature and a sol-
vent: antisolvent ratio of 1:40. Regarding the materials, a drug amount
of 100mg was convenient with superiority for 0.2% w/v F68 either as a
single stabilizer or as a mixture with PVP-K25 at 1:1 or 1:2 w: w ratios.
3.4. Eﬀects of freeze-drying on particle size and stability
Aggregation of the selected LNs did not occur for 1 week upon
storage at 4 °C, and nanoscale particle size was preserved (Table 3).
However, MPS increased for all the selected samples compared to the
MPS measured on the day of preparation: for LN5 MPS increased from
246.5 to 276.1 nm, for LN12 MPS increased from 253.4 to 283.4 nm,
while for LN13 MPS increased from 265.6 to 294.1 nm. These changes
indicate that although particle size remains in the nanosuspension
range, a particle size increment of 28.5–30 nm need to be considered
over time. This storage time was enough for the nanosuspension to be
transferred into the freeze-dryer and converted into dried nano-
particles.
Other LNs were transformed into DLNs. The selected DLNs were
easily redistributed to their original volume at nanosized range with
accepted PDI (Table 4) and higher ZP than corresponding nanosus-
pensions, probably due to an enhanced speciﬁc interaction between
LOR and the polymeric stabilizers during drying and hence stability
(Kim and Lee, 2010). The higher ZP could assure the physical stability
of DLNs.
3.5. Morphology
The morphology of pure LOR showed an irregular rod-like crystal
shape with a particle size above 5 μm with some aggregation, resulting
in a broad range of size distribution. In the PMs drug particles clearly
Table 2
Mean particle size (MPS), polydispersity index (PDI) and zeta potential (ZP) for LOR and LNs.
Sample LOR (mg) Stabilizer type Stabilizer concentration (% w/v) MPS (nm) PDI ZP (mV)
LOR 100 – – 4607.5 ± 41.7 0.71 ± 0.18 −7.73 ± 5.28
LN1 100 PVP-K25 0.2 4900 ± 71.98 0.98 ± 0.028 −13.4 ± 4.02
LN2 100 HPMC 0.2 4212 ± 14.14 0.767 ± 0.18 −11.9 ± 4.51
LN3 100 SLS 0.2 1496.3 ± 17.457 0.414 ± 0.11 −54 ± 7.75
LN4 100 Tween 80 0.2 414.9 ± 9.02 0.217 ± 0.03 −23 ± 6.51
LN5 100 F68 0.2 246.5 ± 1.83 0.133 ± 0.03 −6.51 ± 3.98
LN6 100 F68 0.4 288.3 ± 37.33 0.104 ± 0.01 −6.36 ± 4.45
LN7 100 F68 0.6 325.4 ± 28.20 0.198 ± 0.01 −12.1 ± 5.91
LN8 100 PVP-K25+ SLS 0.2+0.2 589.3 ± 12.66 0.226 ± 0.03 −58.7 ± 8.54
LN9 100 F68+ SLS 0.2+0.2 557.4 ± 31.47 0.196 ± 0.03 −67.2 ± 8.14
LN10 50 F68+PVP-K25 0.2+0.2 306.7 ± 14.97 0.158 ± 0.11 −27.8 ± 5.08
LN11 75 F68+PVP-K25 0.2+0.2 276.5 ± 2.69 0.108 ± 0.02 −4.81 ± 4.11
LN12 100 F68+PVP-K25 0.2+0.2 253.4 ± 1.27 0.123 ± 0.01 −11.14 ± 4.89
LN13 100 F68+PVP-K25 0.2+0.4 265.6 ± 20.79 0.122 ± 0.03 −18.10 ± 3.85
LN14 100 F68+PVP-K25 0.2+0.6 307.25 ± 7.28 0.166 ± 0.01 −23.6 ± 5.07
LN15 100 Tween80+PVP-K25 0.2+0.2 423.4 ± 15.06 0.202 ± 0.02 −22.9 ± 4.39
Table 3
Mean particle size (MPS), polydispersity index (PDI) and zeta potential (ZP) for
selected LNs after 7 days of storage at 4 °C.
Sample MPS (nm) PDI ZP (mV)
LN5 276.1 ± 17.11 0.137 ± 0.05 −7.8 ± 3.36
LN12 283.4 ± 14.32 0.144 ± 0.02 −17.4 ± 5.23
LN13 294.1 ± 11.61 0.141 ± 0.04 −20.6 ± 7.46
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aggregated, resulting in large particle sizes. DLNs were characterized by
short rod shape particles in the nanorange. The surfaces of DLNs were
smooth due to the uniform drug dispersion at the molecular level. SEM
images also show some excess crystals appearing on the surface (Fig. 2).
3.6. Structural investigations (XRPD, DSC and FT-IR)
Pure LOR XRPD diﬀractogram displayed intense crystalline 2θ
peaks between 5° and 30°, indicating its crystalline nature. The PMs
showed the characteristic crystalline diﬀraction peaks of LOR, while the
characteristic crystalline peaks disappeared in case of DLNs, producing
a halo and a diﬀused pattern typical of an amorphous material (Fig. 3).
The values indicating the degree of crystallinity also revealed sig-
niﬁcant changes of the crystal structure for DLNs. Compared to LOR,
DLN5 and DLN12 showed a degree of crystallinity of approximately
37%, while DLN13, characterized by highest level of amorphicity, had a
degree of crystallinity of 18.14%. The crystallinity of DLNs containing
PVP-K25 decreased to half when the polymer concentration increased
two-fold (i.e. DLN12 versus DLN13).·These observations support that
the crystalline structure vanishes as a result of the precipitation and
drying processes (Colombo et al., 2017).To evaluate the eﬀects of the
excipients and freeze-drying on XRPD diﬀractograms of DLNs, the
stabilizers F68 and PVP-K25, as well as their combinations were ultra-
sonicated and freeze-dried under the same conditions applied for the
preparation of DLNs. The XRPD diﬀractograms for freeze-dried F68
showed the characteristic peaks of F68 (2θ=19.1° and 23.3°) either
alone or in combination with PVP-K25 at 1:1 and 1:2 weight ratios
(Fig. 4). However, the signal intensity of F68 peaks were less pro-
nounced on DLNs' diﬀractograms, and PVP-K25 maintained the amor-
phous state. These investigations support that the amorphous structure
of DLNs, as demonstrated by the diﬀractograms, is related to the lower
level of LOR's crystallinity rather than to the eﬀects of the stabilizers
used (Ramos Yacasi et al., 2017).
To evaluate the thermal behavior of the nanoparticles prepared,
DSC thermograms of the raw materials, PMs and DLNs were taken
(Fig. 4a). Pure LOR exhibited a single sharp endothermic peak at
135.5 °C, corresponding to its melting point. F68 also showed a single
peak for its melting point at 55 °C. For PVP-K25, the peak corre-
sponding to the evaporation of water appeared in the temperature
range of 50–80 °C (Ruan et al., 2005). The absence of LOR peaks in PMs
may be attributed to the eﬀect of F68 as it melted at 55 °C and dissolved
LOR during further heating. This hypothesis is supported by the XRPD
results, showing that crystalline LOR is present in PMs (Ahuja et al.,
2007). DLNs showed two broad peaks, one at 55–60 °C and the other at
110 °C. These thermal events could be related to TRE, to the interac-
tions between the drug, the stabilizer and TRE during freeze-drying, to
the phenomenon of the drug's dissolving in the stabilizer or to the
transformation into the amorphous state (Chang et al., 2017; Dolenc
et al., 2009). DSC thermograms of the ultasonicated, freeze-dried ex-
cipients (Fig. 4b) revealed speciﬁc interactions between the compo-
nents of excipient mixtures during freeze-drying. Moreover, a change in
the thermogram of TRE in freeze-dried samples containing PVP-K25,
i.e. FD-(PVP-K25/TRE) and FD-(F68/PVP-K25/TRE) revealed the
Table 4
Mean particle size (MPS), polydispersity index (PDI) and zeta potential (ZP) for
the selected DLNs after reconstitution in water.
Sample MPS (nm) PDI ZP (mV)
DLN5 406.80 ± 16.32 0.240 ± 0.018 −25.80 ± 5.87
DLN12 353.55 ± 31.75 0.195 ± 0.037 −22.35 ± 5.62
DLN13 441.42 ± 37.90 0.246 ± 0.023 −20.70 ± 4.82
LOR PM1 PM2
DLN5 DLN13DLN12
Fig. 2. SEM images of LOR, PM1, PM2, DLN5, DLN12 and DLN13.
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absence of the endothermic peak characteristic of TRE at 210 °C due to
interactions (Cardona et al., 1997; Imamura et al., 2008; Taylor, 1998).
FT-IR spectral analysis was performed to study the possibility of
molecular interactions between LOR and the stabilizers. The FT-IR
spectra of the raw materials and of DLNs are shown in Fig. 5. Pure LOR's
FT-IR spectrum is characterized by principal bands at approximately
997 cm−1 for Aryl CeCl stretching and 1227 cm−1 for eCeN stretching
of aryl N. There are two characteristic bands at 1560 and 1703 cm−1
that correspond to CeO bonds of the amide or ester groups. Bands from
3000 to 2850 cm−1 correspond to the CH bond. On the other hand,
PVP-K25 showed important bands at 3468 cm−1 (OeH stretching vi-
brations), 2954 cm−1 (CeH stretching) as well as broad peaks at
1666 cm−1 (C]O stretching) and at 1290 cm−1 (CeN stretching vi-
brations). F68 showed peaks at 3503 cm−1 (OH stretching), 2889 cm−1
(CeH stretching) and 1116 cm−1 related to CeO bonds stretching (Lin
et al., 2010; Wu et al., 2009; Yu et al., 2011). PMs spectra showed the
characteristic peaks of pure LOR, indicating negligible interactions
between the API and the excipients. On the other hand, DLNs showed
major diﬀerences at 3532, 2900–2982, 1700 and 997–1171 cm−1.
These alternations maybe related to the stabilizers, i.e. interactions of
the excipients with LOR during freeze-drying. To reveal the ambiguity,
subtracted curves were generated by subtracting the FT-IR spectra of
the excipients including TRE from the spectra of corresponding DLNs
and PMs (Fig. 6). The peak for LOR in the subtracted curves of PMs was
identical to the peak of pure LOR. However, the subtracted curves of
DLNs showed an additional peak at 3532 cm−1 related to NeH and a
peak at 3100 cm−1 which was also related to weak stretching OH
bonds. Peak weakening and broadening were observed at 1703 and
(a) (b)
FD-F68
FD-PVP-K25
FD-F68/PVP-K25 (1:1)
FD-F68/PVP-K25 (1:2)
DLN13
DLN12
DLN5
PM2
PM1
PVP-K25
F68
LOR
Fig. 3. (a) XRPD diﬀractograms of LOR, F68, PVP-K25, PM1, PM2, DLN5, DLN12 and DLN13. (b) XRPD diﬀractograms of FD-F68, FD-PVP-K25, FD-F68/K25 (1:1)
and FD-F68/K25 (1:2).
FD-F68/PVP/K25/TRE
FD-PVP-K25/TRE
FD-F68/PVP-K25
FD-F68
FD-PVP-K25
FD-TRE
FD-F68/TRE
(b)
(a)
LOR
F68
PVP-K25
PM1
PM2
DLN5
DLN12
DLN13
Fig. 4. (a) DSC thermograms of LOR, F68, PVP-k25, PM1, PM2, DLN5, DLN12 and DLN13. (b) DSC thermograms of ultasonicated, freeze-dried excipients; F68, PVP-
K25, TRE, F68/PVP-K25, F68/TRE, PVP-K25/TRE and F68/PVP-K25/TRE.
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Fig. 5. FT-IR spectra of LOR, F68, PVP-K25, PM1, PM2, DLN5, DLN12 and DLN13.
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Fig. 6. FT-IR spectra produced by subtracting the FT-IR spectra of the excipients from the spectra of corresponding DLNs and PMs.(A) DLN5-Excipients, (B) DLN12-
Excipients, (C) DLN13-Excipients, (D) PM1-Excipients, (E) PM2-Excipients compared to (F) PVP-K25, (G) F68 and (H) LOR.
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1500 cm−1. These changes were observed in all DLNs regardless of the
type of stabilizers used, indicating that this eﬀect may be attributed to
freeze-drying and TRE. These investigations revealed the presence of
intermolecular hydrogen bond and dipole-dipole interactions, although
no chemical decompositions were detected.
3.7. Solubility and dissolution studies
LOR is characterized by pH-dependent solubility. It has a high so-
lubility at low pH where pyridine nitrogen undergoes protonation.
Compared to pure LOR, DLNs showed enhanced saturation solubility in
water and in PBS of pH 7.4 (Table 5). Compared to pure LOR, solubility
of nanoparticles was increased by approximately 5.5, 8.6 and 15.4-fold
for DLN5, DLN12 and DLN13, respectively, in water and 9.3, 8.0 and
8.6-fold for DLN5, DLN12 and DLN13 in PBS of pH 7.4. Water solubility
was increased by increasing concentrations of PVP-K25. This may be
attributed to the anti-plasticizing activity of PVP-K25, which retards the
formation of the crystal lattice.
Based on these solubility data, the sink conditions were not con-
sidered. To maintain the sink conditions, saturation solubility of the
drug should be at least three times the drug's concentration (Phillips
et al., 2012). Moreover, sink conditions applied in dissolution tests lead
to rapid dissolution rates for nanosuspensions, hampering the dis-
crimination of the dissolution proﬁles of diﬀerent samples (Liu et al.,
2013).
Fig. 7 shows the dissolution proﬁles for LOR, PMs and DLNs at PBS
of pH 7.4. Poor dissolution of LOR results in only 6% of the drug dis-
solving in 120min. PM1 and PM2 showed higher dissolving of the drug
(20.3 and 17.7%, respectively) due to the increased wettability of the
drug powder.
DLNs showed higher drug release than pure LOR and PMs. Between
30 and 42% of the drug was detected to be released in the ﬁrst 10min,
followed by no further signiﬁcant dissolution because the sink condi-
tions were not applied. Enhanced drug release can be attributed to
particle size reduction which produces a higher surface area for dis-
solution, based on the Noyes-Whitney equation, and possibly to better
wettability (Jinno et al., 2006; Noyes and Whitney, 1897). In a careful
estimation, DLN5 showed the highest rate of dissolution, which may be
related to F68 which forms micelles that increase dissolution. On the
other hand, decreasing concentrations of PVP-K25 were found to im-
prove dissolution due to increased viscosity around the stagnant layer.
Additionally, the amorphous form is characterized by better solubility
compared to the crystalline form (Lindfors et al., 2007).
The enhancement of dissolution eﬃciency at diﬀerent time points
and RD60 can be noticed as well. MDT values were decreased (Table 6).
These experiments demonstrate a higher and faster dissolution of DLNs.
4. Conclusion
LNs and DLNs suitable for further processing were successfully
prepared by using 0.2% w/v F68 as a single stabilizer or as a component
of a mixture of stabilizers containing 0.2 or 0.4% w/v PVP-K25. Process
and material parameters were demonstrated to have a pronounced ef-
fect on controlling the properties of the ﬁnal nanoparticles. Regarding
the type(s) of stabilizer(s), two-component mixtures of stabilizers were
found to promote a reduction in particle size, as seen in the case of SLS
combined with PVP-K25 or F68, whereas this eﬀect was not observed
for Tween 80 or F68 combined with PVP-K25. On the other hand, in-
creasing the concentration of F68 above 0.2%w/v resulted in larger
particle size. Drug content was also demonstrated to have a consider-
able eﬀect on MPS. Process parameters of nanosuspension production
and drying also aﬀected MPS and ZP of nanoparticles signiﬁcantly.
Time length, power and temperature of the ultrasonication process
were conﬁrmed to have a signiﬁcant eﬀect. Furthermore, we have de-
monstrated that freeze-drying induces interactions between LOR and
the excipients, with TRE behaving as a cryoprotectant compound. Based
on our experimental data, we conclude that optimized material and
process parameters make it possible to produce dried nanoparticles
with MPS and PDI falling in the required range. Moreover, ZPs and the
dry state itself guarantee the stability of these nanoparticles. The pre-
pared DLNs exhibited a signiﬁcant reduction of LOR's crystallinity with
enhanced solubility and dissolution compared to the pure drug. Thus,
our study supports that is a feasible approach to prepare dried lor-
atadine nanoparticles suitable for designing eﬀective drug preparations,
including oral, ophthalmic or nasal dosage forms.
Table 5
Saturation solubility (μg/ml) of pure LOR and DLNs in distilled water and PBS
of pH 7.4.
Sample Water PBS of pH 7.4
LOR 2.22 ± 0.001 0.49 ± 0.001
PM1 2.13 ± 0.001 1.87 ± 0.008
PM2 7.06 ± 0.024 4.26 ± 0.011
DLN5 12.17 ± 0.007 4.57 ± 0.063
DLN12 19.11 ± 0.045 3.90 ± 0.008
DLN13 34.26 ± 0.004 4.19 ± 0.001
Fig. 7. Dissolution behaviors of LOR, PM1, PM2, DLN5, DLN12 and DLN13 at PBS, pH 7.4.
Table 6
%DE, MDT and RD60 min for LOR and DLNs.
Sample %DE30 %DE60 %DE120 MDT RD60min
LOR 3.309 4.141 5.014 16.439 –
PM1 13.567 17.5671 18.574 6.615 4.243
PM2 8.873 11.797 14.375 16.882 2.849
DLN5 36.662 40.137 43.547 5.0185 9.693
DLN12 27.153 28.726 28.996 0.514 6.937
DLN13 32.876 33.858 33.387 1.218 8.177
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